



Research Paper

Skeletal muscle-specific *Keap1* disruption modulates fatty acid utilization and enhances exercise capacity in female mice

Takahiro Onoki^{a,b}, Yoshihiro Izumi^c, Masatomo Takahashi^c, Shohei Murakami^a, Daisuke Matsumaru^a, Nao Ohta^a, Sisca Meida Wati^a, Nozomi Hatanaka^d, Fumiki Katsuoka^d, Mitsuharu Okutsu^e, Yutaka Yabe^b, Yoshihiro Hagiwara^b, Makoto Kanzaki^f, Takeshi Bamba^c, Eiji Itoi^b, Hozumi Motohashi^{a,*}

^a Department of Gene Expression Regulation, IDAC, Tohoku University, Sendai, 980-8575, Japan

^b Department of Orthopaedic Surgery, Tohoku University School of Medicine, Sendai, 980-8575, Japan

^c Division of Metabolomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, 812-8582, Japan

^d Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan

^e Graduate School of Science, Nagoya City University, Nagoya, 467-8501, Japan

^f Graduate School of Biomedical Engineering, Tohoku University, Sendai, 980-8575, Japan



ARTICLE INFO

Keywords:

Exercise
Skeletal muscle
KEAP1-NRF2 system
Fatty acid
Beta-oxidation

ABSTRACT

Skeletal muscle health is important for the prevention of various age-related diseases. The loss of skeletal muscle mass, which is known as sarcopenia, underlies physical disability, poor quality of life and chronic diseases in elderly people. The transcription factor NRF2 plays important roles in the regulation of the cellular defense against oxidative stress, as well as the metabolism and mitochondrial activity. To determine the contribution of skeletal muscle NRF2 to exercise capacity, we conducted skeletal muscle-specific inhibition of KEAP1, which is a negative regulator of NRF2, and examined the cell-autonomous and non-cell-autonomous effects of NRF2 pathway activation in skeletal muscles. We found that NRF2 activation in skeletal muscles increased slow oxidative muscle fiber type and improved exercise endurance capacity in female mice. We also observed that female mice with NRF2 pathway activation in their skeletal muscles exhibited enhanced exercise-induced mobilization and β -oxidation of fatty acids. These results indicate that NRF2 activation in skeletal muscles promotes communication with adipose tissues via humoral and/or neuronal signaling and facilitates the utilization of fatty acids as an energy source, resulting in increased mitochondrial activity and efficient energy production during exercise, which leads to improved exercise endurance.

1. Introduction

Physical exercise produces wide-ranging health benefits. The loss of skeletal muscle mass with aging, which is known as sarcopenia, diminishes muscle strength and exercise capacity, which seriously affects the quality of life of elderly people and is a major sign of age-associated frailty [1,2]. While regular physical exercise is the best and only way to maintain skeletal muscle mass, a recent study reported that exercise intolerance and rapid skeletal muscle energetic decline during exercise are characteristics of age-associated frailty [3], suggesting that when an elderly person begins to suffer from exercise intolerance, a vicious circle is started in which reduction in skeletal muscle mass leads to further

deterioration of exercise intolerance. Increasing exercise endurance capacity by improving skeletal muscle energy metabolism is expected to be an effective means of breaking this vicious cycle. However, because of the multilayered regulation of skeletal muscle metabolism by remote organs and tissues, including the liver, pancreas, adipose tissues, neuronal tissues and gut microbiota [4,5], our knowledge on specific target molecules in specific tissues for the modulation of skeletal muscle metabolism remains limited.

The KEAP1-NRF2 system plays a central role in the defense mechanism against oxidative stress and xenobiotic electrophiles [6]. NRF2 is a potent transcription activator for a number of stress-response and cytoprotective genes, and KEAP1 is a negative regulator of NRF2. KEAP1

* Corresponding author. Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai, 980-8575, Japan.

E-mail address: hozumim@med.tohoku.ac.jp (H. Motohashi).

<https://doi.org/10.1016/j.redox.2021.101966>

Received 28 October 2020; Received in revised form 23 March 2021; Accepted 31 March 2021

Available online 5 April 2021

2213-2317/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

is a substrate recognition subunit of the CUL3-based ubiquitin E3 ligase and ubiquitinates NRF2 for proteasomal degradation under unstressed conditions, thereby suppressing NRF2 activity at low levels. When cells are exposed to oxidative stress and/or electrophilic chemicals, KEAP1 activity decreases, and stabilized NRF2 translocates into the nucleus and activates the transcription of its target genes. In addition to the thoroughly analyzed antioxidant function of NRF2, this protein has been demonstrated to exert anti-inflammatory functions [7,8], as well as regulating the metabolism and mitochondrial activity [9–12].

Previous studies described the roles played by NRF2 in skeletal muscle regarding regeneration [13], stem cell function [14], mitochondrial biogenesis [15], autophagy [16] and exercise capacity [17] based on analyses of *Nrf2* knockout mice. The contribution of NRF2 to skeletal muscle performance and exercise capacity was also investigated by the pharmacological induction of NRF2 with electrophilic chemicals [11,18]. Although these reports suggest that systemic activation of NRF2 increases exercise capacity and is eventually beneficial for the prevention of age-associated sarcopenia and frailty, activation of skeletal muscle NRF2 reduces skeletal muscle mass [11], indicating the complexity of NRF2 involvement in skeletal muscle physiology and differential contributions of NRF2 in each tissue and organ to exercise capacity in the whole body.

Because we consider that maintaining the healthy condition of skeletal muscles is a primary prerequisite for the prevention of sarcopenia and frailty, we attempted to elucidate how NRF2 activation in skeletal muscles impacts local and systemic metabolism and exercise capacity. To this end, we generated skeletal muscle-specific *Keap1* knockout mice (*Keap1^{F/F}.Mlc1f-Cre* mice; MK mice) and investigated their muscle fiber composition, metabolism, gene expression and exercise capacity. These analyses demonstrated that skeletal muscle-specific NRF2 activation by *Keap1* disruption enhances the mobilization and oxidation of fatty acids (FAs) and increases exercise capacity.

2. Materials and methods

2.1. Animal studies

Keap1-knockdown (*Keap1*-KD) mice [19] were provided by Professor Masi Yamamoto at Tohoku University. *Keap1^{F/F}* mice were provided by Professor Shyam Biswal at Johns Hopkins University [20]. *Mlc1f-Cre* mice were provided by Professor Steve Burden at New York University [21]. All the mice utilized in this study were in the C57BL/6J genetic background. These mice were bred and housed under specific pathogen-free conditions with standard animal maintenance according to the regulations of *The Standards for Human Care and Use of Laboratory Animals of Tohoku University* (Tohoku University, 2007. Standards for human care and use of laboratory animals of Tohoku University. Tohoku University, Sendai, Japan.) and *The Guidelines for Proper Conduct of Animal Experiments* by the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Science Council of Japan, 2006. Guidelines for proper conduct of animal experiments. Science Council of Japan, Ministry of Education, Culture, Sports, Science, and Technology of Japan, Tokyo, Japan.). Mice were examined at 2–5 months of age. After mice were sacrificed by cervical dislocation, the soleus (Sol), plantaris (Plant), gastrocnemius (GC) muscles, heart, lung and liver were subsequently dissected for analysis. The tibia length was measured using caliper. Blood was drawn from anesthetized mice using heparinized capillary tubes (Fisher Scientific) into the microtube within 0.5 M EDTA (pH 7.4, 2 μ L) and centrifuged (3000 rpm for 15 min at 4 °C) to isolate plasma. Samples were frozen in liquid nitrogen and stored at –80 °C until analysis.

2.2. SDH staining

Plant and Sol muscles were dissected and quickly frozen in isopentane (#26405-65, Nacalai Tesque) that was prechilled in liquid

nitrogen. The muscles were sectioned into 10- μ m slices using cryostat (CM3050S, Leica Biosystems, Hesse, Germany). SDH staining was performed as previously reported with slight modifications [22]. Sections were stained in a solution containing 0.5 mg/mL nitroblue tetrazolium (#N5514, Sigma-Aldrich) and 50 mM sodium succinate in 50 mM phosphate buffer at 37 °C for 20 min. The SDH-positive area was defined by a fixed threshold and automatically quantified at 100x magnification under optical microscopy with BZ II Analyzer software (BZ-9000 series, Keyence, Osaka, Japan).

2.3. Immunofluorescence

MHC I immunofluorescence staining was conducted by using frozen sections. The sections were fixed in ice-cold 4% PFA on ice for 10 min. After washing with ice-cold PBS, the sections were permeabilized by ice-cold 3% NP-40 on ice for 10 min. Then, the sections were incubated with 5% normal goat serum (#31872, Invitrogen) in PBS for 1 h at room temperature for blocking non-specific staining, followed by overnight incubation with mouse anti-MHC I antibody (BA-F8) (1:100, DSHB) in blocking solution at 4 °C. After washing with PBS and additional fixing in 4% paraformaldehyde for 2 min followed by PBS wash, sections were incubated with Alexa Fluor 594-labelled anti-mouse IgG antibody (1:200, #A11005, Thermo Fisher Scientific) in blocking solution for 1 h at room temperature. From this procedure, sections were protected from light and mounted in Permafluor mountant (#TA-030-FM, Thermo Fisher Scientific). Histological samples were imaged by a Keyence BZ-9000 fluorescence microscope (BZ-9000 series, Keyence, Osaka, Japan). The area of MHC I positive muscle fiber was quantified by using NIH ImageJ software (<http://rsb.info.nih.gov/ij/>).

3. Skeletal muscle performance

3.1. Grip force test

Mice were allowed to grasp a horizontal bar with their forelimbs or grid with the four limbs. The bar and grid were connected with a dynamometer (GPM-101B, Melquest, Toyama, Japan). Grip strength was measured by pulling a tail of a mouse slowly backwards until the mouse released its limbs from the instrument. The maximum tension value out of 5 trials was recorded in grams as one measurement, which was repeated 10 times within a week. The mean value of the 10 measurements was calculated and normalized to the body weight.

3.2. Hanging inverted grid test

Mice were placed on the grid wire for 1 min to acclimate the grid. Then, the grid was inverted gently with a mouse, and the time to fall was recorded. If a mouse kept hanging more than 1 h, we censored the recording. If the hanging time was less than 1 min, which was considered an accidental fall, the hanging time was reexamined. The measurement trials were limited to 10 times a day. If the record did not reach 1 min, the maximum record out of 10 trials was adopted. The test was conducted twice within a week, and the mean value of the two tests was calculated as a final result. The Hang Impulse Score was calculated as body weight (g) \times hanging time (min).

3.3. Time to exhaustion

Before an exercise bout, mice were placed in the treadmill for acclimation (MK-680, Muromachi Kikai, Tokyo, Japan). For male *Keap1*-KD mice, adaptive training was conducted on the first day (starting speed at 15 m/min for 10 min followed by 22 m/min for 15 min). The treadmill test was conducted on the second day. The starting speed was 5 m/min for 3 min, and the speed was increased by 5 m/min every 3 min until the speed reached 28 m/min. The maximum speed of 28 m/min was continued, and the time to exhaustion was measured.

Table 1DEGs for each group ranked by fold change. FDR >0.1 and log₂ [fold change] ≥ 1 or < -1.

Gene symbol	Gene description	log ₂ [fold change]	FDR
exercise vs. sedentary in Cntl mice			
<i>Atf3</i>	Activating transcription factor 3	3.656	5.660E-02
<i>Ppargc1a</i>	PPARG coactivator 1 alpha	3.248	6.400E-04
<i>Nr4a3</i>	Nuclear receptor subfamily 4 group a member 3	2.483	7.250E-02
<i>Otud1</i>	OTU deubiquitinase 1	2.232	7.250E-02
<i>Trim36</i>	Tripartite motif containing 36	-2.215	7.640E-02
<i>Arhgap8</i>	Rho GTPase activating protein 8	2.195	5.660E-02
<i>Impact</i>	Impact RWD domain protein	2.095	8.270E-03
<i>Tctex1d2</i>	Tctex1 domain containing 2	-1.862	7.250E-02
<i>Irs2</i>	Insulin receptor substrate 2	1.783	7.640E-02
<i>Slc19a2</i>	Solute carrier family 19 member 2	-1.543	7.280E-02
<i>Tnfsf9</i>	TNF superfamily member 9	1.528	8.640E-02
<i>Slc20a1</i>	Solute carrier family 20 member 1	1.469	7.250E-02
<i>Sik1</i>	Salt inducible kinase 1	1.462	8.640E-02
exercise vs. sedentary in MK mice			
<i>Ppargc1a</i>	PPARG coactivator 1 alpha	2.608	6.530E-03
<i>Il12rb1</i>	Interleukin 12 receptor subunit beta 1	2.215	7.980E-02
<i>Impact</i>	Impact RWD domain protein	1.760	3.170E-02
<i>Clec2e</i>	C-type lectin domain family 1 member e	-1.723	3.170E-02
<i>Slc20a1</i>	Solute carrier family 20 member 1	1.552	7.980E-02
<i>Dscam</i>	DS cell adhesion molecule	1.195	9.590E-02

For *Keap1^{F/F}:Mlc1f-Cre* (MK) mice, their control *Keap1^{F/F}* (Cntl) mice and female *Keap1-KD* mice, training was performed on four consecutive days: 8 m/min for 10 min twice on the first day, 9 m/min for 10 min twice on the second day, 10 m/min for 10 min twice on the third day and 12 m/min for 10 min twice on the fourth day. On the fifth day, a treadmill test was conducted. The starting speed was 5 m/min for 3 min, and the speed was increased by 5 m/min every 3 min until the speed reached 20 m/min. The maximum speed of 20 m/min was continued, and the time to exhaustion was measured.

Mice were considered to be exhausted when the mice remained on the grid area for more than 10 s. If a mouse ran more than 4 h, we ended the recording except for female *Keap1-KD* mice and their control WT mice, for which the recording was stopped at 6 h.

3.4. Immunoblot analysis

Skeletal muscle samples were homogenized by sonicator in denaturing lysis buffer containing 210 mM Tris-HCl, pH 6.8, 6.2% sodium dodecyl sulfate (SDS), 21.6% glycerol and 0.36 M dithiothreitol on ice. Muscle homogenates were boiled at 100 °C for 5 min and centrifuged at 1000 g for 15 min. Supernatants were used for analysis, and the loading amount of each sample was adjusted according to the intensity of α-tubulin, which was used as a loading control. The proteins were separated by SDS-PAGE gel and transferred to polyvinylidene fluoride (PVDF) membranes (#IPVH00010, Millipore) by using a Bio-Rad transfer apparatus (Mini-PROTEAN® Tetra System, Bio-Rad, Hercules,

Table 2

Primers and probes used in real-time PCR.

Gene	Primer/Probe	Sequence (5' - 3')
Mouse <i>Acox2</i>	Forward primer	CAATGACTTCCATCAAGTGGTG
	Reverse primer	GTCTATGTTTTCGAAGCCCATC
Mouse <i>β-Actin</i>	Forward primer	CGGTCCCGATGCCCTGAGGCTCTT
	Reverse primer	CGTCACACTTCATGATGGAATGA
Mouse <i>Cytochrome b</i>	Forward primer	GGCTACGTCCTCCATGAGGAC
	Reverse primer	GAAGCCCCCTCAAATTCATTGCGAC
Mouse <i>Gbe1</i>	Forward primer	CAAGAGCTATACGGACTACCGAGT
	Reverse primer	CGCTGCGCTCAGAATCTAGT
Mouse <i>Gclc</i>	Forward primer	ATCTGCAAAGGCGGCAAC
	Reverse primer	ACTCTCTGTCAGCTGGCTC
	Probe	FAM-ACGGGTGCAGCAAGGCCCA-TAMRA
Mouse <i>Gclm</i>	Forward primer	TGGAGCAGCTGTATCAGTGG
	Reverse primer	AAATCTGGTGGCATCACACA
Mouse <i>Keap1</i>	Forward primer	CCCATGAGGCATCACCGTAG
	Reverse primer	CATAGCCTCCGAGGACGTAG
	Probe	FAM-GGATTACTGTGCCACAGGGCAAG-TAMRA
Mouse <i>Nfe2l2</i>	Forward primer	CAAGACTTGGGCCACTTAAAAGAC
	Reverse primer	AGTAAGGCTTCCATCCTCATCAC
	Probe	FAM-AGGCGGCTCAGCACCTTGTATCTTGA-TAMRA
Mouse <i>Nqo1</i>	Forward primer	AGCTGGAAGCTGCAGACCTG
	Reverse primer	CCTTTCAGAATGGCTGGCA
	Probe	FAM-ATTTTCAGTTCCTCCATTGCAGTGGTTGGG-TAMRA
Mouse <i>Phka1</i>	Forward primer	TGGCAACAGAACTAGCACACTC
	Reverse primer	GATTTCATCAGGCCCTCTGTG
Mouse <i>Srxn1</i>	Forward primer	AGCCTGGTGACACGATC
	Reverse primer	AGGAATAGTAGTAGTCGCCA
Mouse <i>Txnrd1</i>	Forward primer	AGAAAGTGCTGTCTTGGATTTTG
	Reverse primer	ACACGTTCTCCGAGACCC
	Probe	FAM-TCTGGTCCCAAGAGGAGTCCGGTGTG-TAMRA

CA, USA). After the transfer of protein, the membrane was blocked in 5% (w/v) skim milk in Tris-buffered saline (TBS) containing 0.1% (w/v) Tween 20 (TBST) for 1 h. The membranes were incubated with primary antibodies diluted with 5% (w/v) skim milk in TBST overnight at 4 °C. The antibodies used in this study were as follows: rabbit anti-cytochrome c (Cyt c) (1:1250, #11940, Cell Signaling Technology), mouse anti-Complex IV-subunit (Cox IV) (1:1250, #A21348, Thermo Fisher Scientific) and mouse anti-α-tubulin (1:3000, #T6199, Sigma-Aldrich). Primary antibodies against MHC I (BA-F8) (1:100, DSHB), MHC IIa (SC-71) (1:100, DSHB), and MHC IIb (BF-F3) (1:100, DSHB) were purchased from Developmental Studies Hybridoma Bank at the University of Iowa. The primary KEAP1 antibody was a generous gift from Professor Masi Yamamoto at Tohoku University [23]. The

membranes were washed and incubated with 5% skim milk in TBST containing peroxidase-conjugated secondary antibody for 1 h at room temperature. The bands were detected with ECL prime (GE Healthcare) or Chemi-Lumi One L (Nacalai Tesque) using ImageQuant LAS 4000 mini (GE Healthcare, Chicago, IL, USA). Band intensities were quantified using NIH ImageJ software (<http://rsb.info.nih.gov/ij/>).

3.5. RNA extraction and real-time PCR

Total RNA was isolated from skeletal muscle by using Sepazol-RNA I Super G (#09379-55, Nacalai Tesque) according to the manufacturer's protocol, and RNA quantity was measured using a Nano Drop (ND-2000, Thermo Fisher Scientific, Waltham, MA, USA). cDNA was synthesized from total RNA using ReverTra Ace® qPCR RT Master Mix with gDNA Remover (#FSQ-301, TOYOBO CO., LTD., Osaka, Japan). Real-time PCRs were conducted on an Applied Biosystems 7300 Real-Time PCR System (7300 M, Thermo Fisher Scientific, Waltham, MA, USA) using THUNDERBIRD® SYBR qPCR Mix (#QPS-201, TOYOBO Co., Ltd., Osaka, Japan) or THUNDERBIRD® Probe qPCR Mix (#QPS-101, TOYOBO Co., Ltd., Osaka, Japan). *β-Actin* was employed for normalization. All primers used for real-time PCR are described in Table 2.

3.6. RNA purification and RNA-sequence analysis

Total RNA was isolated as described above and further purified using the RNeasy® MinElute® Cleanup Kit (#74204, QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Subsequently, 0.8 µg of total RNA was subjected to rRNA removal using the NEB Next® rRNA Depletion Kit (#E6310S, New England BioLabs, Ipswich, MA, USA). cDNA sequencing libraries were subsequently prepared using the SureSelect Strand-Specific RNA library preparation kit (#G9691B, Agilent Technologies, Santa Clara, CA, USA) with a modified protocol omitting the polyA selection step. The libraries were quantified by the qMiSeq method [24] and sequenced on a HiSeq2500 System (Illumina, San Diego, CA, USA) to generate 76-bp single-end reads. Approximately 30 million reads per sample were obtained. Raw data in fastq sequencing files were mapped and counted using the Galaxy platform [25–27]. Expression level estimations were reported for each sample as fragments per kilobase of transcript sequence per million mapped fragments (FPKM). iDEP (Integrated Differential Expression and Pathway analysis, version 0.91) was used for data analysis and identification of DEGs. A heat map of DEGs was created using GraphPad Prism 8 (version 8. 4. 3, GraphPad Software, San Diego, CA, USA).

3.7. DNA purification and mitochondrial DNA quantification

Skeletal muscle samples were digested by proteinase K in lysis buffer containing 0.1 M Tris-HCl (pH 8.0), 20 mM EDTA, pH 8.0, 0.2 M NaCl and 0.2% sodium dodecyl sulfate (SDS) at 55 °C overnight. Genomic DNA was isolated from skeletal muscle lysate by phenol-chloroform extraction and ethanol precipitation. DNA quantity was measured by a Nano Drop (ND-2000, Thermo Fisher Scientific, Waltham, MA, USA). Real-time PCRs were performed by an Applied Biosystems 7300 Real-Time PCR System (7300 M, Thermo Fisher Scientific, Waltham, MA, USA) using THUNDERBIRD® SYBR qPCR Mix (#QPS-201, TOYOBO CO., LTD., Osaka, Japan). The gene dose of *Cytochrome b* encoded in mitochondrial DNA was quantified and normalized against the gene dose of *β-Actin* encoded in nuclear DNA.

3.8. Sample preparation for metabolome and lipidome analyses

Total metabolites and lipids were extracted from plasma and Sol muscle according to the Bligh and Dyer method with minor modifications [28]. Briefly, each 50 µL of plasma was mixed with 910 µL of methanol, 15 µL of internal standard (IS) solution A (chloroform) containing DG 15:0–18:1 (d₇) (0.23 nmol) and TG 15:0–18:1 (d₇)–15:0

(0.53 nmol), 15 µL of IS solution B (methanol/chloroform, 1/1, v/v) containing FA 16:0 (¹³C₁₆) (0.15 nmol) and MG 18:1 (d₇) (1.5 nmol), and 10 µL of IS solution C (water) containing 10-camphorsulfonic acid (2.0 nmol) and piperazine-1,4-bis(2-ethanesulfonic acid) (2.0 nmol). The samples were centrifuged at 16,000 g at 4 °C for 5 min, and the supernatant (400 µL) was collected in clean tubes. After mixing with 400 µL of chloroform and 320 µL of water, phase separation of aqueous and organic layers was performed via centrifugation (16,000 g, 4 °C, 5 min). The aqueous (upper) layer (500 µL) was transferred into a clean tube. After the aqueous layer extracts were evaporated under vacuum, the dried extracts were stored at –80 °C until the analysis of hydrophilic metabolites. Prior to analysis, the dried aqueous layer was reconstituted in 50 µL of water. The organic (lower) layer (250 µL) was placed in another tube and diluted twice with methanol and stored at –80 °C until hydrophobic metabolite analysis.


Dissected Sol muscles were snap frozen in liquid nitrogen. Frozen muscles were plunged into 1 mL of cold methanol (–30 °C) containing 10-camphorsulfonic acid (1.5 nmol) and piperazine-1,4-bis(2-ethanesulfonic acid) (1.5 nmol) as ISs and homogenized with zirconia beads at 20 Hz for 1 min using a tissue homogenizer (ball mill mixer MM301, Retsch, Haan, Germany). Subsequently, the homogenate sample was centrifuged at 16,000 g and 4 °C for 5 min. Then, 600 µL supernatants were transferred to another tube, and 600 µL of chloroform and 480 µL of water were added. After centrifugation at 16,000 g and 4 °C for 5 min, 800 µL of the upper layer was isolated and used for hydrophilic metabolite analysis.

3.9. Metabolome and lipidome analyses

Anionic polar metabolites (e.g., organic acids, nucleotides, and 3-hydroxybutyric acid) were analyzed via ion chromatography (Dionex ICS-5000⁺ HPLC system, Thermo Fisher Scientific) with a Dionex IonPac AG11-HC-4 µm guard column (2 mm i.d. × 50 mm, 4 µm particle size, Thermo Fisher Scientific) and a Dionex IonPac AS11-HC-4 µm column (2 mm i.d. × 250 mm, 4 µm particle size, Thermo Fisher Scientific) coupled with a Q Exactive, high-performance benchtop quadrupole Orbitrap high-resolution tandem mass spectrometer (Thermo Fisher Scientific) (IC/HRMS/MS) [29]. Cationic polar metabolites (e.g., amino acids, bases, and nucleosides) were analyzed via liquid chromatography (Nexera X2 UHPLC system, Shimadzu Co., Kyoto, Japan) with a Discovery HS F5 column (2.1 mm i.d. × 150 mm, 3 µm particle size, Merck) coupled with a Q Exactive instrument (PFPP-LC/HRMS/MS) [57]. MGs, DGs, and TGs were analyzed using supercritical fluid chromatography (SFC) (Nexera UC system, Shimadzu Co.) equipped with an ACQUITY UPC² Torus diethylamine (DEA) (3.0 mm i.d. × 100 mm, 1.7 µm particle size, Waters, Milford, MA) and triple quadrupole mass spectrometry (TQMS, LCMS-8060, Shimadzu Co.) (DEA-SFC/MS/MS) in multiple reaction monitoring (MRM) mode [30]. FAs were analyzed using an SFC (Shimadzu Co.) with an ACQUITY UPC² HSS C18 SB column (3.0 mm i.d. × 100 mm, 1.8 µm particle size, Waters) coupled with a TQMS (Shimadzu Co.) (C18-SFC/MS/MS) in MRM mode [31]. Xcalibur 4.2.47 (Thermo Fisher Scientific), LabSolutions, version 5.9 (Shimadzu Co.), MRMPROBS 2.86 [32], and Microsoft Excel 2010 were used for data processing. The details of the analytical conditions for the analyses of hydrophilic and hydrophobic metabolites are described in the Supporting Information.

3.10. Statistical analysis

All data are presented as the mean ± SD. The sample size (*n*) of each experiment is described in each corresponding figure legend. Statistical analyses were generated using Student's *t*-test (two-sided unpaired), one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test and log-rank (Mantel-Cox) test with GraphPad Prism 8 (GraphPad Software). *P*-values less than 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) were considered to be significant.



(caption on next page)

Fig. 1. Systemic KEAP1 inhibition increases skeletal muscle mass and enhances endurance exercise capacity.

Two-sided Student's *t*-test was conducted for statistical significance. **P* < 0.05, ***P* < 0.01, ****P* < 0.001, ns; not significant.

A. Immunoblot analysis of KEAP1 protein in plantaris muscle (Plant). (*n* = 3 mice per group). Tubulin was detected as a loading control. Intensities of the immunoblot bands (upper panel) were quantified using image J software (lower panel). Mean and SD are indicated. Mean values of WT mice are set as 1. WT; wild-type mice, KD; *Keap1*-knockdown mice.

B. RT-PCR for measuring mRNA expression of *Keap1* and *Nqo1* in gastrocnemius muscle (GC) (*n* = 6 mice per group). β -Actin was employed for normalization. Mean and SD are indicated. Mean values of WT mice are set as 1.

C. Body weight. (*n* = 11 mice per group). Mean and SD are indicated.

D. Skeletal muscle wet weights normalized by the length of the tibia. GC, Plant and soleus (Sol) muscles were examined (*n* = 5 mice per group). Mean and SD are indicated.

E. Protocol for the treadmill test. On the first day, adaptive training was undertaken using a condition of 15 m/min for 10 min followed by 22 m/min for 15 min. On the second day, a treadmill test was undertaken. A starting speed was 5 m/min, and the speed was increased by 5 m/min every 3 min until the speed reached 28 m/min. The maximum speed of 28 m/min was continued, and the time to exhaustion was measured.

F. Time to exhaustion at the speed of 28 m/min (*n* = 15 mice per group). Mean and SD are indicated.

4. Results

4.1. Systemic inhibition of the *Keap1* gene in mice increases skeletal muscle mass and enhances exercise capacity

Previous studies reported that the administration of NRF2-inducing electrophiles enhances exercise capacity in mice [11,18]. To determine whether genetic activation of NRF2 recapitulates this effect, we used *Keap1*-knockdown (*Keap1*-KD) mice [33]. We first verified reduced expression of KEAP1 protein and mRNA in the skeletal muscle of *Keap1*-KD mice (Fig. 1A and B). *Nqo1*, one of the typical target genes of NRF2, was determined to be upregulated in *Keap1*-KD skeletal muscle (Fig. 1B), suggesting that the NRF2 pathway is activated in skeletal muscles of *Keap1*-KD mice. The body weight of *Keap1*-KD mice was observed to be smaller than that of wild-type (WT) mice (Fig. 1C), which was due to less fat mass according to the previous study [33]. Skeletal muscle wet weight normalized by tibia length was not different for gastrocnemius (GC) and plantaris (Plant) muscles, which are known as fast glycolytic muscles, between *Keap1*-KD and WT mice (Fig. 1D). In contrast, soleus (Sol) muscle, known as slow oxidative muscle, in *Keap1*-KD mice was significantly heavier than in WT mice (Fig. 1D). To evaluate exercise capacity, we conducted a treadmill test using the protocol shown in Fig. 1E. Male *Keap1*-KD mice exhibited significantly longer running times than male WT mice did (Fig. 1F), suggesting that the NRF2 pathway activation due to systemic KEAP1 inhibition increased exercise capacity.

4.2. Generation of skeletal muscle-specific *Keap1* knockout mice

To further investigate the effects of NRF2 activation specifically in skeletal muscles, we generated skeletal muscle-specific *Keap1* knockout mice through the Cre-loxP recombination system. *Mlc1f*-Cre mice [21] were crossed with *Keap1* floxed mice [20] to generate *Keap1*^{F/F}; *Mlc1f*-Cre mice (MK mice). *Keap1*^{F/F} mice were employed as a control (Cntl mice). We verified the reduction of KEAP1 protein and mRNA in skeletal muscle in MK mice (Fig. 2A and B). Meanwhile, the mRNA expression of the NRF2 target genes *Nqo1* and *Txnrd1* was significantly upregulated in MK mice (Fig. 2B). No apparent differences were observed in the expression levels of *Keap1* or *Nqo1* in other organs (Fig. 2C and D), indicating that the *Keap1* inhibition and consequent NRF2 pathway activation were induced specifically in the skeletal muscle.

4.3. Skeletal muscle-specific *Keap1* disruption alters the content of skeletal muscle fiber MHC subtypes on soleus muscle in female mice

Skeletal muscle-specific *Keap1* disruption did not alter body weight or skeletal muscle wet weight normalized by tibia length (Fig. 3A–C), which was different from the results obtained with *Keap1*-KD mice. To determine whether there were any changes in the contents of muscle fiber subtypes in MK mice, we detected each fiber subtype by

immunoblot analysis. In male mice, there were no apparent changes in the content of muscle fiber subtypes except for a modest decrease in MHC IIa, known as a fast-oxidative muscle fiber subtype, in GC muscle (Fig. 3D and E). In female mice, the MHC IIa fiber was significantly decreased in Sol muscle, although there were no changes in GC. These results indicated that the contents of muscle fiber subtypes were substantially altered in female MK mice, and we utilized female mice for further investigation.

4.4. Skeletal muscle-specific *Keap1* disruption enhances mitochondrial activity

The reduction in MHC IIa suggested a relative increase in MHC I, a slow-oxidative muscle fiber subtype, in the Sol muscle of female MK mice. Indeed, % distribution of MHC I was higher in MK mice than Cntl mice by immunofluorescence using anti-MHC I antibody in Sol muscle (Fig. 4A and B). Because anti-MHC IIa antibody did not work for us, MHC I-negative fibers in Sol muscle were regarded as MHC IIa-positive based on an observation that MHC IIb was not detected in Sol muscle. We then examined mitochondrial proteins and DNA and conducted histological assessment of succinate dehydrogenase (SDH) activity to evaluate mitochondrial biogenesis and activity, respectively. The expression levels of mitochondrial proteins, Cytochrome *c* (Cyt *c*) and COX4, were examined using immunoblot analysis. Cyt *c* protein levels were higher in GC and Sol muscles of MK mice than in those of Cntl mice (Fig. 4C). Mitochondrial DNA, examined as the Cytochrome *b* (*Mt-cyb*) gene dose, in GC and Sol muscles were comparable between Cntl and MK mice (Fig. 4D). SDH activity in Plant muscle was higher in MK mice than in Cntl mice (Fig. 4E and F). Sol exhibited a similar tendency, although the difference was not significant. These results suggest that skeletal muscle-specific *Keap1* disruption promotes mitochondrial metabolic activity, rather than biogenesis, which is consistent with a previous finding that NRF2 pathway activation in skeletal muscle increased oxygen consumption but did not alter mitochondrial DNA levels [11].

Metabolomic profiling of the soleus muscle in skeletal muscle-specific *Keap1* knockout female mice.

Because increased mitochondrial activity was suggested in skeletal muscles of female MK mice, we investigated the metabolic alterations in MK mice by conducting metabolome analysis using Sol muscle. Although NRF2 is a well-known activator of glutathione synthesis, reduced and oxidized glutathione levels did not exhibit significant differences (Fig. 5A). The uric acid level tended to be higher in MK female Sol muscle (Fig. 5B), which was consistent with a previous finding obtained in forestomach epithelia of *Keap1*-KD mice [9]. Other metabolites of central metabolism did not show any significant differences between MK mice and Cntl mice (data not shown), except for nucleoside triphosphates. The nucleoside triphosphates ATP, GTP and CTP were unexpectedly all reduced in the Sol muscles of MK mice, whereas nucleoside di- and monophosphate levels were mostly comparable between the two groups (Fig. 5C). Considering the increased SDH activity (see Fig. 4E and F) and increased oxygen consumption [11] in




Fig. 2. Generation of skeletal muscle-specific *Keap1* knockout mice. Cntl; *Keap1*^{F/F} mice; MK; *Keap1*^{F/F}.*Mlc1f-Cre* mice. Two-sided Student's *t*-test was conducted for statistical significance. **P* < 0.05, ***P* < 0.01, ****P* < 0.001, ns; not significant.

A. Immunoblot analysis of KEAP1 protein in GC muscle. (*n* = 3 mice per group). Tubulin was detected as a loading control. Intensities of the immunoblot bands (left panel) were quantified using image J software (right panel). Mean and SD are indicated. Mean values of Cntl mice are set as 1.

B. RT-PCR for measuring mRNA expression of *Keap1*, *Nqo1* and *Txnrd1* in gastrocnemius muscle (*n* = 8 mice per group). β -Actin was employed for normalization. Mean and SD are indicated. Mean values of Cntl mice are set as 1.

C, D. RT-PCR for measuring mRNA expression of *Keap1* (C) and *Nqo1* (D) in representative tissues (*n* = 3 mice per group). β -Actin was employed for normalization. Mean and SD are indicated. Mean values of Cntl mice are set as 1.

Keap1-deficient muscles, we surmise that decreased ATP production due to mitochondrial uncoupling and/or increased ATP consumption account for the decreased levels of nucleoside triphosphates.

4.5. Skeletal muscle-specific *Keap1* disruption enhances exercise endurance capacity but not muscle strength

We asked how *Keap1* disruption in skeletal muscles, which was accompanied by a significant reduction in nucleoside triphosphates, including ATP, affects exercise capacity. MK mice and their control mice were subjected to physical performance tests, *i.e.*, the grip force test, inverted grid hanging test and treadmill running test. The grip force test was employed for measuring muscle strength, while the inverted grid hanging test and treadmill running test were used for measuring muscle endurance capacity. The grip force test did not indicate any differences between MK and Cntl mice (Fig. 6A). In contrast, MK mice exhibited dramatic gain of hanging capacity in the inverted grid hanging test (Fig. 6B and C) and significant extension of running time in the treadmill running test (Fig. 6D and E). These results suggest that skeletal muscle-specific *Keap1* disruption enhances exercise endurance capacity in female mice. As for male mice, physical performance tests did not give any conclusive results, implying that impacts of skeletal muscle-specific disruption of *Keap1* are smaller than those of unidentified fluctuating factors in individual male mice.

To elucidate cell-autonomous and non-cell-autonomous function of NRF2 for the improvement of physical performance, we examined skeletal muscle mass and conducted physical performance test using female *Keap1*-KD mice for comparison. Treadmill running test was conducted according to the protocol shown in Fig. 6D. The body weight was almost comparable between *Keap1*-KD and WT mice (Fig. 7A). Slight increases in Sol muscle mass and in grip strength were observed in *Keap1*-KD mice (Fig. 7B and C) but not in MK mice (see Figs. 3C and 6A), whereas improvements in hanging capacity and treadmill running capacity were similarly observed in *Keap1*-KD (Fig. 7D–F) and MK mice (see Fig. 6B, C and 6E). Thus, muscle NRF2 activity accounts for the improvement of muscle endurance capacity, and extra-muscle NRF2 activity accounts for the increase of muscle mass and strength although the effect size was small.

4.6. Transcriptomic profiling of soleus muscle in skeletal muscle-specific *Keap1* knockout female mice with or without acute exercise

Because exercise endurance was markedly increased in MK mice despite the reduced ATP levels in resting skeletal muscle, we expected that the exercise-induced response was augmented in skeletal muscles of MK mice and conferred elevated endurance on MK mice. We examined the changes in gene expression induced by acute exercise in the Sol muscles of MK and Cntl mice. MK and Cntl mice were randomly allocated into two groups, the sedentary and acute exercise groups, and the Sol muscles of these mice were utilized for RNA-seq analysis (Fig. 8A).

Following the criteria of FDR > 0.1, log₂FC > 1 or < -1 and protein-encoding genes, the transcriptome was compared between sedentary and acute exercise groups in each genotype. Thirteen genes and 6 genes were identified as differentially expressed genes (DEGs) in Cntl and MK mice, respectively (Table 1). Contrary to our expectation, the exercise-induced changes in gene expression were attenuated in Sol muscles of MK mice (Fig. 8B), suggesting that reactive oxygen species (ROS), which are regarded as mediators of exercise-induced signaling that induces trophic effects on skeletal muscles, are quenched in skeletal muscles in MK mice due to the antioxidant function of NRF2.

RT-PCR was conducted using mouse Sol muscles obtained in the second independent experiment shown in Fig. 8A. *Keap1* expression in Cntl mice was decreased after the acute exercise to the similar level of MK mice whereas *Nfe2l2* expression was not changed (Fig. 8C). In the sedentary groups, NRF2 target genes in Sol muscles were mostly up-regulated in MK mice compared with those in Cntl mice, except for *Gclc*





Fig. 3. Muscle weight and fiber types of skeletal muscle-specific *Keap1* knockout mice

Cntl; *Keap1*^{F/F} mice, MK; *Keap1*^{F/F}.*Mlc1f*-Cre mice. Two-sided Student's *t*-test was conducted for statistical significance. **P* < 0.05, ***P* < 0.01, ns; not significant. A. Body weight of Cntl and MK mice. (male: *n* = 17 mice per group, female: *n* = 25 for Cntl mice and *n* = 22 for MK mice). Mean and SD are indicated.

B, C. Skeletal muscle wet weights normalized by the length of the tibia. GC (B) and Sol (C) are shown. (male: *n* = 7 mice per group, female: *n* = 10 for Cntl mice and *n* = 9 for MK mice). Mean and SD are indicated.

D. Immunoblot analysis of MHC IIa and IIb in GC muscle. (*n* = 3 mice per group). Tubulin was detected as a loading control. Intensities of the immunoblot bands (upper panel) were quantified using image J software (lower panel). Mean and SD are indicated. Mean values of Cntl mice are set as 1.

E. Immunoblot analysis of MHC I and IIa in Sol muscle. (*n* = 3 mice per group). Tubulin was detected as a loading control. Intensities of the immunoblot bands (upper panel) were quantified using image J software (lower panel). Mean and SD are indicated. Mean values of Cntl mice are set as 1.



(caption on next page)

Fig. 4. Mitochondrial biogenesis and activity in skeletal muscle-specific *Keap1* knockout mice.

Cntl; *Keap1*^{F/F} mice, MK; *Keap1*^{F/F}:*Mlc1f*-Cre mice. Two-sided Student *t*-test was conducted for statistical significance. **P* < 0.05, ns; not significant.

A, B. Immunofluorescence with MHC I antibody of Sol muscle. Representative results from 5 mice per group are shown (A). Area of MHC I fiber were quantified by using image J software (F). Mean and SD are indicated

C. Immunoblot analysis of Cytochrome *c* (Cyt *c*) and Cytochrome *c* oxidase subunit 4 (Cox4) in GC and Sol muscles (n = 3 mice per group). Tubulin was detected as a loading control. Intensities of the immunoblot bands (upper panel) were quantified using image J software (lower panel). Mean and SD are indicated. Mean values of Cntl mice are set as 1.

D. Quantification of mitochondrial DNA normalized to genomic DNA in GC and Sol muscles (n = 5 mice per group). *Cytochrome b* and β -*Actin* were amplified as representatives of mitochondrial and genomic DNA, respectively (n = 5 mice per group). Mean and SD are indicated. Mean values of Cntl mice were set as 1.

E, F. Succinate dehydrogenase (SDH) staining of Plant and Sol muscles. Representative results from 5 mice per group are shown (E). Staining intensities were quantified (F). Mean and SD are indicated.




Fig. 5. Metabolome analysis using Sol muscle of skeletal muscle-specific *Keap1* knockout mice.

Cntl; *Keap1*^{F/F} mice, MK; *Keap1*^{F/F}:*Mlc1f*-Cre mice. Two-sided Student's *t*-test was conducted for statistical significance. **P* < 0.05, ns; not significant.

A. Quantities of reduced and oxidized glutathione (GSH and GSSG, respectively) and their ratios (n = 3 mice per group). Mean and SD are indicated. Mean values of Cntl mice are set as 1 for GSH and GSSG quantities.

B. Uric acid quantity (n = 3 mice per group). Mean and SD are indicated. Mean values of Cntl mice are set as 1.

C. Quantities of nucleoside tri-, di- and monophosphates (n = 3 mice per group). Mean and SD are indicated. Mean values of Cntl mice are set as 1.

and *Gclm* (Fig. 8D). *Gclc* and *Gclm* encode catalytic and modifier subunits of a rate-limiting enzyme of glutathione synthesis, γ -glutamylcysteine synthetase, respectively. Comparable expression of *Gclc* and *Gclm* between Cntl and MK mice, implying that NRF2 contribution to *Gclc* and *Gclm* expression in Sol muscle is not big enough in the sedentary condition, may explain why glutathione levels were not different in the Sol muscles of Cntl and MK mice in the sedentary condition (see Fig. 5A). *Gbe1* and *Phka1*, described as NRF2 target genes in skeletal muscles, were expected to facilitate glycogen utilization [11]. In the sedentary groups, *Gbe1* and *Phka1* tended to be upregulated in MK mice, but statistical significance was not reached (Fig. 8D). *Srxn1*, another NRF2 target gene, was also marginally upregulated in MK mice. One of the enzymes catalyzing β -oxidation of FAs, *Acox2*, was found to be remarkably increased in MK mice compared with Cntl mice, which is consistent with the findings of a recent report describing that *Acox2* is a target gene of NRF2 [34].

In the acute exercise groups, MK mice exhibited elevated expression of these NRF2 target genes, including *Gclc* and *Gclm*, compared with Cntl

mice (Fig. 8D). Upregulation of the NRF2 target genes in Cntl mice in the acute exercise group compared with those in the sedentary group was not apparent in this experimental setting (Fig. 8D) although previous studies described that muscle contraction and exercise increase NRF2 activity in skeletal muscle [35–38].

However, these transcriptomic changes induced by acute exercise could not explain the increased endurance capacity of MK mice. Considering that NRF2 pathway activation in skeletal muscles has systemic impacts, serving to improve glucose tolerance and increase energy expenditure [11], soluble factors and/or neural signals were likely to be emitted from NRF2-activated skeletal muscles. We suspected that such signals derived from NRF2-activated skeletal muscles acted on liver and/or adipose tissues to supply nutrients to skeletal muscles. Namely, systemic metabolism appeared to be a key to underlying the increase in the exercise capacity of MK mice.




Fig. 6. Skeletal muscle-specific *Keap1* disruption enhances endurance exercise capacity.

Cntl; *Keap1*^{F/F} mice, MK; *Keap1*^{F/F}.*Mlc1f*-Cre mice. Two-sided Student *t*-test (A, C) and Log-rank (Mantel-Cox) test (B, D) were conducted for statistical significance. ** $P < 0.01$, ns; not significant.

A. Grip strength of forelimbs and four limbs normalized by body weight (BW) ($n = 8$ for Cntl mice and $n = 15$ for MK mice). Mean and SD are indicated.

B. Inverted grid hanging test ($n = 8$ for Cntl mice and $n = 15$ for MK mice).

C. Hang impulse score calculated as hanging time (min) × BW (g) ($n = 8$ for Cntl mice and $n = 15$ for MK mice). Mean and SD are indicated.

D. Protocol for the treadmill test. The adaptive training was undertaken for four consecutive days: 8 m/min for 10 min twice on the first day, 9 m/min for 10 min twice on the second day, 10 m/min for 10 min twice on the third day and 12 m/min for 10 min twice on the fourth day. On the fifth day, a treadmill test was undertaken. The starting speed was 5 m/min, and the speed was increased by 5 m/min every 3 min until the speed reached 20 m/min. The maximum speed of 20 m/min was continued, and the time to exhaustion was measured.

E. Treadmill running test ($n = 8$ for Cntl mice and $n = 15$ for MK mice).




Fig. 7. Systemic KEAP1 inhibition increases skeletal muscle mass and enhances endurance exercise capacity in female mice.

WT; wild-type mice, KD; *Keap1*-knockdown mice. Two-sided Student *t*-test (A, C) and Log-rank (Mantel-Cox) test (B, D) were conducted for statistical significance. * $P < 0.05$, ns; not significant.

A. Body weight. ($n = 5$ mice per group). Mean and SD are indicated.

B. Skeletal muscle wet weights normalized by the length of the tibia. Gastrocnemius (GC), plantaris (Plant) and soleus (Sol) muscles were examined ($n = 5$ mice per group). Mean and SD are indicated.

C. Grip strength of forelimbs and four limbs normalized by body weight (BW) ($n = 5$ mice per group). Mean and SD are indicated.

D. Inverted grid hanging test ($n = 5$ mice per group).

E. Hang impulse score calculated as hanging time (min) \times BW (g) ($n = 5$ mice per group). Mean and SD are indicated.

F. Treadmill running test ($n = 5$ mice per group).




Fig. 8. RNA-seq analysis using Sol muscle of skeletal muscle-specific *Keap1* knockout mice.

A. Experimental design. Both sedentary and exercise group mice underwent 2-day adaptive training. The exercise group mice were run for 2 h at 20 m/min and were sacrificed for sampling just after running on day 3. Sedentary group mice were killed and sampled without running on day 3. **B.** Heat map of differentially expressed genes in Sol muscles of Cntl mice from sedentary vs acute exercise groups. Cntl; *Keap1*^{F/F} mice, MK; *Keap1*^{F/F}:*Mlc1f-Cre* mice, sed; sedentary group, exe; acute exercise group.

C, D. RT-PCR for measuring mRNA expression of *Keap1* and *Nfe2l2* (Nrf2) (C) and NRF2 target genes (D). *β-Actin* was employed for normalization. Mean and SD are indicated (Cntl: *n* = 5 for sed and exe mice, MK: *n* = 4 for sed mice and *n* = 6 for exe mice). Mean values of sed Cntl mice are set as 1. One-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test was conducted for statistical significance. **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001, ns; not significant.

4.7. Skeletal muscle-specific *Keap1* disruption facilitates the exercise-induced *β*-oxidation of FAs

We examined changes in systemic metabolism with or without exercise by measuring the plasma metabolites of MK and Cntl mice (see

Fig. 8A). Neither genotype nor exercise had significant effects on the plasma levels of glucose and its intermediary metabolites (Fig. 9A and B). However, when we calculated fold changes of metabolite levels with vs. without acute exercise, we observed a significantly lower fold change of lactate in MK mice than in Cntl mice (Fig. 9C). Specifically, in this




Fig. 9. Metabolome analysis using plasma from skeletal muscle-specific *Keap1* knockout mice with or without acute exercise. **A, B.** Glucose and its intermediary metabolites of glycolysis (**A**) and tricarboxylic acid cycle (**B**) in plasma ($n = 3$ mice per group). Mean and SD are indicated. One-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test was conducted for statistical significance. **C.** Fold change in plasma lactate in the exercise group vs. the sedentary group. The mean and SD of the fold change were calculated from those of lactate shown in panel **A**. Cntl; *Keap1^{F/F}* mice, MK; *Keap1^{F/F}:Mlc1f-Cre* mice, sed; sedentary group, exe; acute exercise group. * $P < 0.05$, ns; not significant.

exercise protocol, the plasma lactate levels were not changed in Cntl mice but decreased in MK mice, suggesting that the skeletal muscles of MK mice utilize the glycolytic pathway less during exercise than do those of Cntl mice. Alternatively or simultaneously, the conversion of lactate to glucose in the liver may be facilitated in MK mice.

Considering the enhanced mitochondrial activity in skeletal muscles of MK mice, we suspected that exercise-induced enhancement of fatty acid utilization can explain the increased exercise endurance of MK mice. To support this hypothesis, we conducted lipidome analysis of the plasma samples. The total concentration of FAs was increased by exercise in both genotypes (Fig. 10A). Exercise did not alter the plasma levels of other lipid species, including monoacylglycerols (MGs), diacylglycerols (DGs) or triacylglycerols (TGs), regardless of genotype (Fig. 10A). Measurement of individual FAs indicated that MK mice had a greater response to exercise than Cntl mice; among 8 FAs quantified in the lipidome analysis, six FAs were significantly elevated in MK plasma, whereas 4 were elevated in Cntl plasma (Fig. 10B). Moreover, after acute exercise, MK mice showed a robust increase in the plasma level of 3-hydroxybutyric acid, which was generated from the β -oxidation of FAs (Fig. 10C). These results strongly suggest that MK mice are more efficient in utilizing FAs as an energy source during exercise via enhanced mobilization of FAs and their subsequent catabolism by β -oxidation.

5. Discussion

This study demonstrated a beneficial role of KEAP1 inhibition in

skeletal muscle for endurance capacity, which was accompanied by increased FA mobilization and β -oxidation. To the best of our knowledge, this study is the first to investigate the impact of skeletal muscle-specific KEAP1 inhibition on exercise capacity. Considering a highly strict relationship between KEAP1 and NRF2, we consider that the beneficial effects of KEAP1 inhibition are mostly attributable to NRF2 activation because the currently reported *in vivo* phenotypes caused by KEAP1 inhibition are all abolished by simultaneous inhibition of NRF2 [39–41] and because *Nrf2*-deficient mice indeed exhibit impaired exercise endurance [18]. NRF2 activation in skeletal muscles is likely to facilitate interorgan communications between skeletal muscles and adipose tissues via humoral factors and/or neuronal signaling, resulting in increased fatty acid mobilization from adipose tissues. NRF2 activation in skeletal muscles is also likely to exert a cell-autonomous effect, *i.e.*, increasing mitochondrial activity, which probably accounts for the enhanced β -oxidation of FAs. With these results, this study demonstrates multimodal metabolic regulation by NRF2, which enables increased exercise endurance.

It is well established that muscle contractions during exercise produce ROS [42]. Although the precise mechanisms governing ROS production have not been elucidated, mitochondria are regarded as a predominant source of ROS, especially through complexes I and III of the electron transport chain [43–45]. While excessive ROS production by prolonged or high-intensity exercise results in oxidative damage to skeletal muscle [46], recent studies indicate that exercise-induced ROS play a physiological role and act as an important mediator for skeletal




Fig. 10. Lipidome analysis using plasma from skeletal muscle-specific *Keap1* knockout mice with or without acute exercise.

Cntl; *Keap1*^{F/F} mice, MK; *Keap1*^{F/F}.*Mlc1f*-Cre mice, sed; sedentary group, exe; acute exercise group. Mean and SD are indicated. One-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test was conducted for statistical significance. * $P < 0.05$, ** $P < 0.01$, ns; not significant.

A. Total amount of fatty acids (FAs), monoglycerides (MGs), diglycerides (DGs) and triglycerides (TGs) in plasma ($n = 3$ mice per group).

B. Individual fatty acids in plasma ($n = 3$ mice per group).

C. 3-Hydroxybutyric acid quantity in plasma ($n = 3$ mice per group).

muscle adaptations [47] and that muscle contraction and exercise increase NRF2 protein levels and activity via ROS production [35,37]. In our experimental setting, however, we could not detect such tendency of NRF2 pathway activation after acute exercise in Cntl mice (see Fig. 7D). Because forced activation of NRF2 by *Keap1* disruption in MK mice suppressed the exercise-induced transcriptional response (see Fig. 7B and C), we believe that optimal activation of NRF2 balances maintaining beneficial ROS levels required for physiological signaling and limiting harmful ROS levels for the protection of tissues from oxidative damage.

NRF2 has been shown to activate mitochondrial activity by controlling substrate availability [48], which supports our current results that the Sol and Plant muscles of MK mice exhibited higher mitochondrial activity, as measured by SDH staining, but did not show a significant increase in mitochondrial DNA. Moreover, facilitation of fatty acid oxidation has been suggested as a major cause of NRF2-mediated enhancement of mitochondrial activity [49], which also appears to be consistent with our results. We found that 3-hydroxybutyric acid was significantly increased in the plasma of MK mice after acute exercise (see

Fig. 10C) and that skeletal muscle of MK mice exhibited upregulation of *Acox2* (see Fig. 8D), which encodes the branched-chain acyl-CoA oxidase catalyzing degradation of long branched FAs as the first main enzymatic reaction controlling the β -oxidation flux [50]. Although *Acox1*, which encodes another acyl-CoA oxidase, is abundantly expressed in skeletal muscles and is unlikely to be regulated by NRF2, *Acox2* may contribute to the facilitation of β -oxidation in skeletal muscles.

An important remaining question is how Nrf2 activation in skeletal muscles leads to the increased mobilization of FAs in plasma. Exercise-induced FA elevation is derived from both intramuscular lipids and adipose tissue [51]. The relative contribution of the energy source between intramuscular lipolysis and peripheral adipocyte lipolysis depends on the exercise intensity and duration. For low-intensity exercise, which is likely to correspond to the training protocol in our experimental setting, peripheral lipolysis accounts for most of the fuel source. We surmise that NRF2 activation in skeletal muscles facilitates lipolysis in adipose tissues catalyzed by hormone-sensitive lipase via humoral or neuronal signals during exercise. We could not find any clues to the interorgan communication in our RNA-seq data concerning Sol muscles with or without acute exercise.

Another remaining question is the sex difference of NRF2 contributions in skeletal muscles. After observing that fast-oxidative fiber subtype MHC IIa was notably decreased in MK female mice compared with Cntl female mice but not in males, we focused on females. We do not know the reason why skeletal muscle-specific *Keap1* disruption generates clear differences in fiber subtypes in females but not in males (see Fig. 3E). Many aspects of skeletal muscles, including overall muscle mass, size of cross-sectional area, lipid content and utilization, relative expression of different myosin isoforms, fatigability and gene expression, differ between males and females [52–57]. In particular, the mean proportion of slow oxidative fiber is higher than that of fast glycolytic fiber in females, and the mean proportion of fast glycolytic fiber is higher than that of slow oxidative fiber in males. Furthermore, intramuscular triacylglycerol content and the fatty acid transporter expression levels are higher in women than in men, and women use more lipids during exercise than men [58,59]. These differences might have augmented the impacts of NRF2 activation in the skeletal muscles of female MK mice.

This study has highlighted the roles played by NRF2 in the regulation of fatty acid metabolism via interorgan communication, which is advantageous for endurance exercise. The function of slow oxidative muscle fibers responsible for endurance exercise is especially critical for preventing sarcopenia and frailty in elderly people [60]. We propose that appropriate NRF2 activation is useful for anti-frailty interventions.

Author contributions

T.O. designed the study, conducted the experiments, analyzed the data and wrote an early draft of the paper. S.M., D.M., N.O., S.M.W. and N.H. conducted the experiments. F.K., Y.I., M.T. and T.B. provided critical experimental systems, conducted the experiments, and wrote the paper. M.O., Y.Y. and M.T. conducted the experiments and analyzed the data. Y.H., M.K. and E.I. analyzed the data, supervised the research and wrote the paper. H.M. designed the study, supervised the research, analyzed the data and wrote an early draft of the paper.

Declaration of competing interest

The authors declare no competing financial or non-financial interests.

Acknowledgments

We thank Professor Masi Yamamoto, Professor Shyam Biswal and Professor Steve Burden for providing *Keap1* knockdown mice, *Keap1*

floxed mice and *Mlc1f*-Cre mice, respectively. We also thank the Biomedical Research Cores of the Tohoku University Graduate School of Medicine and Institute of Development, Aging and Cancer for providing technical support. This work was supported by JSPS [grant numbers 18H02621 (HM), 20H04832 (HM) 17H06299 (TB), and 17H06304 (TB)], the Naito Foundation (HM), a research grant from the Princess Takamatsu Cancer Research Fund [grant number 15–24728 (HM)], the Uehara Memorial Foundation (HM), AMED [grant number JP20gm5010002 (HM)] and Japan-Sweden Research Cooperative Program between JSPS and STINT [grant number JPJSBP120195402 (HM)]. The funders had no role in the study design, data collection and analysis, decision to publish or manuscript preparation.

References

- [1] I. Janssen, S.B. Heymsfield, R. Ross, Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability, *J. Am. Geriatr. Soc.* 50 (5) (2002 May) 889–896, <https://doi.org/10.1046/j.1532-5415.2002.50216.x>. PMID: 12028177.
- [2] A.J. Cruz-Jentoft, J.P. Baeyens, J.M. Bauer, Y. Boirie, T. Cederholm, F. Landi, F. C. Martin, J.P. Michel, Y. Rolland, S.M. Schneider, E. Topinková, M. Vandewoude, M. Zamboni, European working group on sarcopenia in older people. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people, *Age Ageing* 39 (4) (2010 Jul) 412–423, <https://doi.org/10.1093/ageing/afq034>. Epub 2010 Apr 13. PMID: 20392703; PMCID: PMC2886201.
- [3] S.C. Lewsey, K. Weiss, M. Schär, Y. Zhang, P.A. Bottomley, T.J. Samuel, Q.L. Xue, A. Steinberg, J. Walston, G. Gerstenblith, R.G. Weiss, Exercise intolerance and rapid skeletal muscle energetic decline in human age-associated frailty, *JCI Insight* (2020 Sep 17) 141246, <https://doi.org/10.1172/jci.insight.141246>. Epub ahead of print. PMID: 32941181.
- [4] J. Frampton, K.G. Murphy, G. Frost, E.S. Chambers, Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function, *Nat Metab* 2 (9) (2020 Sep) 840–848, <https://doi.org/10.1038/s42255-020-0188-7>. Epub 2020 Mar 30. PMID: 32694821.
- [5] C. Laurens, A. Bergouignan, C. Moro, Exercise-released myokines in the control of energy metabolism, *Front. Physiol.* 11 (2020 Feb 13) 91, <https://doi.org/10.3389/fphys.2020.00091>. PMID: 32116795; PMCID: PMC7031345.
- [6] M. Yamamoto, T.W. Kensler, H. Motohashi, The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis, *Physiol. Rev.* 98 (3) (2018 Jul 1) 1169–1203, <https://doi.org/10.1152/physrev.00023.2017>. PMID: 29717933.
- [7] E.H. Kobayashi, T. Suzuki, R. Funayama, T. Nagashima, M. Hayashi, H. Sekine, N. Tanaka, T. Moriguchi, H. Motohashi, K. Nakayama, M. Yamamoto, Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription, *Nat. Commun.* 7 (2016 May 23) 11624, <https://doi.org/10.1038/ncomms11624>. PMID: 27211851; PMCID: PMC4879264.
- [8] T. Suzuki, S. Murakami, S.S. Biswal, S. Sakaguchi, H. Harigae, M. Yamamoto, H. Motohashi, Systemic activation of NRF2 alleviates lethal autoimmune inflammation in scurfy mice, *Mol. Cell Biol.* 37 (15) (2017 Jul 14), <https://doi.org/10.1128/MCB.00063-17>. PMID: 28507037; PMCID: PMC5514445.
- [9] Y. Mitsuishi, K. Taguchi, Y. Kawatani, T. Shibata, T. Nukiwa, H. Aburatani, M. Yamamoto, H. Motohashi, Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming, *Canc. Cell* 22 (1) (2012 Jul 10) 66–79, <https://doi.org/10.1016/j.ccr.2012.05.016>. PMID: 22789539.
- [10] J.D. Hayes, A.T. Dinkova-Kostova, The Nrf2 regulatory network provides an interface between redox and intermediary metabolism, *Trends Biochem. Sci.* 39 (4) (2014 Apr) 199–218, <https://doi.org/10.1016/j.tibs.2014.02.002>. Epub 2014 Mar 16. PMID: 24647116.
- [11] A. Uruno, Y. Yagishita, F. Katsuo, Y. Kitajima, A. Nunomiya, R. Nagatomi, J. Pi, S.S. Biswal, M. Yamamoto, Nrf2-Mediated regulation of skeletal muscle glycogen metabolism, *Mol. Cell Biol.* 36 (11) (2016 May 16) 1655–1672, <https://doi.org/10.1128/MCB.01095-15>. PMID: 27044864; PMCID: PMC4959318.
- [12] M. Tushima, J. Liu, W. Hirao, H. Yamazaki, H. Tomita, K. Itoh, Emerging evidence for crosstalk between Nrf2 and mitochondria in physiological homeostasis and in heart disease, *Arch. Pharm. Res. (Seoul)* 43 (3) (2020 Mar) 286–296, <https://doi.org/10.1007/s12272-019-01188-z>. Epub 2019 Nov 11. PMID: 31712965.
- [13] O. Al-Sawaf, A. Fragoulis, C. Rosen, N. Keimes, E.A. Liehn, F. Hölzle, Y.W. Kan, T. Pufe, T.T. Sönmez, C.J. Wruck, Nrf2 augments skeletal muscle regeneration after ischaemia-reperfusion injury, *J. Pathol.* 234 (4) (2014 Dec) 538–547, <https://doi.org/10.1002/path.4418>. Epub 2014 Sep 16. PMID: 25111334.
- [14] S.B. Shelar, M. Narasimhan, G. Shanmugam, S.H. Litovsky, S.S. Gounder, G. Karan, C. Arulvasu, T.W. Kensler, J.R. Hoidal, V.M. Darley-Usmar, N.S. Rajasekaran, Disruption of nuclear factor (erythroid-derived-2)-like 2 antioxidant signaling: a mechanism for impaired activation of stem cells and delayed regeneration of skeletal muscle, *Faseb. J.* 30 (5) (2016 May) 1865–1879, <https://doi.org/10.1096/fj.201500153>. Epub 2016 Feb 2. PMID: 26839378; PMCID: PMC4836373.
- [15] T.L. Merry, M. Ristow, Nuclear factor erythroid-derived 2-like 2 (NFE2L2, Nrf2) mediates exercise-induced mitochondrial biogenesis and the anti-oxidant response in mice, *J. Physiol.* 594 (18) (2016 Sep 15) 5195–5207, <https://doi.org/10.1113/JP271957>. Epub 2016 May 27. PMID: 27094017; PMCID: PMC5023720.

- [16] D.D. Huang, X.L. Yan, S.D. Fan, X.Y. Chen, J.Y. Yan, Q.T. Dong, W.Z. Chen, N. X. Liu, X.L. Chen, Z. Yu, Nrf2 deficiency promotes the increasing trend of autophagy during aging in skeletal muscle: a potential mechanism for the development of sarcopenia, *Aging (Albany NY)* 12 (7) (2020 Apr 3) 5977–5991, <https://doi.org/10.18632/aging.102990>. Epub 2020 Apr 3. PMID: 32244226; PMCID: PMC7185110.
- [17] L. Wang, S. Yang, L. Yan, H. Wei, J. Wang, S. Yu, A.T. Kong, Y. Zhang, Hypoxia preconditioning promotes endurance exercise capacity of mice by activating skeletal muscle Nrf2, *J. Appl. Physiol.* 127 (5) (2019 Nov 1) 1267–1277, <https://doi.org/10.1152/jappphysiol.00347.2019>. Epub 2019 Sep 5. PMID: 31487225.
- [18] S. Oh, S. Komine, E. Warabi, K. Akiyama, A. Ishii, K. Ishige, Y. Mizokami, K. Kuga, M. Horie, Y. Miwa, T. Iwawaki, M. Yamamoto, J. Shoda, Nuclear factor (erythroid derived 2)-like 2 activation increases exercise endurance capacity via redox modulation in skeletal muscles, *Sci. Rep.* 7 (1) (2017 Oct 10) 12902, <https://doi.org/10.1038/s41598-017-12926-y>. PMID: 29018242; PMCID: PMC5635018.
- [19] H. Okawa, H. Motohashi, A. Kobayashi, H. Aburatani, T.W. Kensler, M. Yamamoto, Hepatocyte-specific deletion of the *keap1* gene activates Nrf2 and confers potent resistance against acute drug toxicity, *Biochem. Biophys. Res. Commun.* 339 (1) (2006 Jan 6) 79–88, <https://doi.org/10.1016/j.bbrc.2005.10.185>. Epub 2005 Nov 8. PMID: 16293230.
- [20] D.J. Blake, A. Singh, P. Kombairaju, D. Malhotra, T.J. Mariani, R.M. Tuder, E. Gabrielson, S. Biswal, Deletion of Keap1 in the lung attenuates acute cigarette smoke-induced oxidative stress and inflammation, *Am. J. Respir. Cell Mol. Biol.* 42 (5) (2010 May) 524–536, <https://doi.org/10.1165/rcmb.2009-0054OC>. Epub 2009 Jun 11. PMID: 19520915; PMCID: PMC2874439.
- [21] G.W. Bothe, J.A. Haspel, C.L. Smith, H.H. Wiener, S.J. Burden, Selective expression of Cre recombinase in skeletal muscle fibers, *Genesis* 26 (2) (2000 Feb) 165–166. PMID: 10686620.
- [22] M.M. Nachlas, K.C. Tsou, E. De Souza, C.S. Cheng, A.M. Seligman, Cytochemical demonstration of succinic dehydrogenase by the use of a new p-nitrophenyl substituted ditetrazole, *J. Histochem. Cytochem.* 5 (4) (1957 Jul) 420–436, <https://doi.org/10.1177/5.4.420>. PMID: 13463314.
- [23] Y. Watai, A. Kobayashi, H. Nagase, M. Mizukami, J. McEvoy, J.D. Singer, K. Itoh, M. Yamamoto, Subcellular localization and cytoplasmic complex status of endogenous Keap1, *Gene Cell.* 12 (10) (2007 Oct) 1163–1178, <https://doi.org/10.1111/j.1365-2443.2007.01118.x>. PMID: 17903176.
- [24] F. Katsuoka, Y. Yokozawa, K. Tsuda, S. Ito, X. Pan, M. Nagasaki, J. Yasuda, M. Yamamoto, An efficient quantitation method of next-generation sequencing libraries by using MiSeq sequencer, *Anal. Biochem.* 466 (2014 Dec 1) 27–29, <https://doi.org/10.1016/j.ab.2014.08.015>. Epub 2014 Aug 28. PMID: 25173513.
- [25] E. Afgan, D. Baker, M. van den Beek, D. Blankenberg, D. Bouvier, M. Čech, J. Chilton, D. Clements, N. Coraor, C. Eberhard, B. Grünig, A. Guerler, J. Hillman-Jackson, G. Von Kuster, E. Rasche, N. Soranzo, N. Turaga, J. Taylor, A. Nekrutenko, J. Goecks, The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update, *Nucleic Acids Res.* 44 (W1) (2016 Jul 8) W3–W10, <https://doi.org/10.1093/nar/gkw343>. Epub 2016 May 2. PMID: 27137889; PMCID: PMC4987906.
- [26] J. Goecks, A. Nekrutenko, J. Taylor, Galaxy Team, Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences, *Genome Biol.* 11 (8) (2010) R86, <https://doi.org/10.1186/gb-2010-11-8-r86>. Epub 2010 Aug 25. PMID: 20738864; PMCID: PMC2945788.
- [27] B. Giardine, C. Riemer, R.C. Hardison, R. Burhans, L. Elnitski, P. Shah, Y. Zhang, D. Blankenberg, I. Albert, J. Taylor, W. Miller, W.J. Kent, A. Nekrutenko, Galaxy: a platform for interactive large-scale genome analysis, *Genome Res.* 15 (10) (2005 Oct) 1451–1455, <https://doi.org/10.1101/gr.4086505>. Epub 2005 Sep 16. PMID: 16169926; PMCID: PMC1240089.
- [28] E.G. Bligh, W.J. Dyer, A rapid method of total lipid extraction and purification, *Can. J. Biochem. Physiol.* 37 (8) (1959 Aug) 911–917, <https://doi.org/10.1139/o59-099>. PMID: 13671378.
- [29] Y. Izumi, F. Matsuda, A. Hirayama, K. Ikeda, Y. Kita, K. Horie, D. Saigusa, K. Saito, Y. Sawada, H. Nakanishi, N. Okahashi, M. Takahashi, M. Nakao, K. Hata, Y. Hoshi, M. Morihara, K. Tanabe, T. Bamba, Y. Oda, Inter-laboratory comparison of metabolite measurements for metabolomics data integration, *Metabolites* 9 (11) (2019 Oct 31) 257, <https://doi.org/10.3390/metabo9110257>. PMID: 31683650; PMCID: PMC6918145.
- [30] H. Takeda, Y. Izumi, M. Takahashi, T. Paxton, S. Tamura, T. Koike, Y. Yu, N. Kato, K. Nagase, M. Shiomi, T. Bamba, Widely-targeted quantitative lipidomics method by supercritical fluid chromatography triple quadrupole mass spectrometry, *J. Lipid Res.* 59 (7) (2018 Jul) 1283–1293, <https://doi.org/10.1194/jlr.D083014>. Epub 2018 May 3. PMID: 29724780; PMCID: PMC6027907.
- [31] T. Ogawa, Y. Izumi, K. Kusumoto, E. Fukusaki, T. Bamba, Wide target analysis of acylglycerols in miso (Japanese fermented soybean paste) by supercritical fluid chromatography coupled with triple quadrupole mass spectrometry and the analysis of the correlation between taste and both acylglycerols and free fatty acids, *Rapid Commun. Mass Spectrom.* 31 (11) (2017 Jun 15) 928–936, <https://doi.org/10.1002/rcm.7862>. PMID: 28370582.
- [32] H. Tsugawa, M. Arita, M. Kanazawa, A. Ogiwara, T. Bamba, E. Fukusaki, MRMPROBS: a data assessment and metabolite identification tool for large-scale multiple reaction monitoring based widely targeted metabolomics, *Anal. Chem.* 85 (10) (2013 May 21) 5191–5199, <https://doi.org/10.1021/ac400515s>. Epub 2013 May 1. PMID: 23581547.
- [33] K. Taguchi, J.M. Maher, T. Suzuki, Y. Kawatani, H. Motohashi, M. Yamamoto, Genetic analysis of cytoprotective functions supported by graded expression of Keap1, *Mol. Cell Biol.* 30 (12) (2010 Jun) 3016–3026, <https://doi.org/10.1128/MCB.01591-09>. Epub 2010 Apr 19. PMID: 20404090; PMCID: PMC2876677.
- [34] E.V. Knatko, M.H. Tatham, Y. Zhang, C. Castro, M. Higgins, S.D. Naidu, C. Leonardi, L. de la Vega, T. Honda, J.L. Griffin, R.T. Hay, A.T. Dinkova-Kostova, Downregulation of Keap1 confers features of a fasted metabolic state, *iScience* 23 (10) (2020 Oct 23) 101638, <https://doi.org/10.1016/j.isci.2020.101638>.
- [35] M. Horie, E. Warabi, S. Komine, S. Oh, J. Shoda, Cytoprotective role of Nrf2 in electrical pulse stimulated C2C12 myotube, *PLoS One* 10 (12) (2015 Dec 14), e0144835, <https://doi.org/10.1371/journal.pone.0144835>. PMID: 26658309; PMCID: PMC4681703.
- [36] A.J. Done, M.J. Gage, N.C. Nieto, T. Traustadóttir, Exercise-induced Nrf2-signaling is impaired in aging, *Free Radic. Biol. Med.* 96 (2016 Jul) 130–138, <https://doi.org/10.1016/j.freeradbiomed.2016.04.024>. Epub 2016 Apr 22. PMID: 27109910.
- [37] P. Wang, C.G. Li, Z. Qi, D. Cui, S. Ding, Acute exercise stress promotes Ref1/Nrf2 signalling and increases mitochondrial antioxidant activity in skeletal muscle, *Exp. Physiol.* 101 (3) (2016 Mar) 410–420, <https://doi.org/10.1113/EP085493>. Epub 2016 Jan 23. PMID: 26682532.
- [38] M. Yamada, M. Iwata, E. Warabi, H. Oishi, V.A. Lira, M. Okutsu, p62/SQSTM1 and Nrf2 are essential for exercise-mediated enhancement of antioxidant protein expression in oxidative muscle, *Faseb. J.* 33 (7) (2019 Jul) 8022–8032, <https://doi.org/10.1096/fj.201900133R>. Epub 2019 Mar 26. PMID: 30913396.
- [39] N. Wakabayashi, K. Itoh, J. Wakabayashi, H. Motohashi, S. Noda, S. Takahashi, S. Imakado, T. Kotsuji, F. Otsuka, D.R. Roop, T. Harada, J.D. Engel, M. Yamamoto, Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation, *Nat. Genet.* 35 (3) (2003 Nov) 238–245, <https://doi.org/10.1038/ng1248>. Epub 2003 Sep 28. PMID: 14517554.
- [40] K. Taguchi, I. Hirano, T. Itoh, M. Tanaka, A. Miyajima, A. Suzuki, H. Motohashi, M. Yamamoto, Nrf2 enhances cholangiocyte expansion in Pten-deficient livers, *Mol. Cell Biol.* 34 (5) (2014 Mar) 900–913, <https://doi.org/10.1128/MCB.01384-13>. Epub 2013 Dec 30. PMID: 24379438; PMCID: PMC4023823.
- [41] S. Murakami, T. Suzuki, H. Harigae, P.H. Romeo, M. Yamamoto, H. Motohashi, Nrf2 activation impairs quiescence and bone marrow reconstitution capacity of hematopoietic stem cells, *Mol. Cell Biol.* 37 (19) (2017 Sep 12), <https://doi.org/10.1128/MCB.00086-17>. PMID: 28674188; PMCID: PMC5599717.
- [42] K.J. Davies, A.T. Quintanilha, G.A. Brooks, L. Packer, Free radicals and tissue damage produced by exercise, *Biochem. Biophys. Res. Commun.* 107 (4) (1982 Aug 31) 1198–1205, [https://doi.org/10.1016/s0006-291x\(82\)80124-1](https://doi.org/10.1016/s0006-291x(82)80124-1). PMID: 6291524.
- [43] Y. Li, M.A. Trush, Diphenyleioidonium, an NAD(P)H oxidase inhibitor, also potentially inhibits mitochondrial reactive oxygen species production, *Biochem. Biophys. Res. Commun.* 253 (2) (1998 Dec 18) 295–299, <https://doi.org/10.1006/bbrc.1998.9729>. PMID: 9878531.
- [44] F.L. Muller, Y. Liu, H. Van Remmen, Complex III releases superoxide to both sides of the inner mitochondrial membrane, *J. Biol. Chem.* 279 (47) (2004 Nov 19) 49064–49073, <https://doi.org/10.1074/jbc.M407715200>. Epub 2004 Aug 17. PMID: 15317809.
- [45] S.K. Powers, M.J. Jackson, Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production, *Physiol. Rev.* 88 (4) (2008 Oct) 1243–1276, <https://doi.org/10.1152/physrev.00031.2007>. PMID: 18923182; PMCID: PMC2909187.
- [46] S.K. Powers, W.B. Nelson, M.B. Hudson, Exercise-induced oxidative stress in humans: cause and consequences, *Free Radic. Biol. Med.* 51 (5) (2011 Sep 1) 942–950, <https://doi.org/10.1016/j.freeradbiomed.2010.12.009>. Epub 2010 Dec 16. PMID: 21167935.
- [47] P. Steinbacher, P. Eckl, Impact of oxidative stress on exercising skeletal muscle, *Biomolecules* 5 (2) (2015 Apr 10) 356–377, <https://doi.org/10.3390/biom5020356>. PMID: 25866921; PMCID: PMC4496677.
- [48] K.M. Holmström, L. Baird, Y. Zhang, I. Hargreaves, A. Chalasani, J.M. Land, L. Stanyer, M. Yamamoto, A.T. Dinkova-Kostova, A.Y. Abramov, Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration, *Biol. Open* 2 (8) (2013 Jun 20) 761–770, <https://doi.org/10.1242/bio.201314853>. PMID: 23951401; PMCID: PMC3744067.
- [49] M.H. Ludtmann, P.R. Angelova, Y. Zhang, A.Y. Abramov, A.T. Dinkova-Kostova, Nrf2 affects the efficiency of mitochondrial fatty acid oxidation, *Biochem. J.* 457 (3) (2014 Feb 1) 415–424, <https://doi.org/10.1042/BJ20130863>. PMID: 24206218; PMCID: PMC4208297.
- [50] Y. Poirier, V.D. Antonenkov, T. Glumoff, J.K. Hiltunen, Peroxisomal beta-oxidation—a metabolic pathway with multiple functions, *Biochim. Biophys. Acta* 1763 (12) (2006 Dec) 1413–1426, <https://doi.org/10.1016/j.bbarmac.2006.08.034>. Epub 2006 Aug 30. PMID: 17028011.
- [51] M. Hargreaves, L.L. Spriet, Skeletal muscle energy metabolism during exercise, *Nat. Metab.* 2 (9) (2020 Sep) 817–828, <https://doi.org/10.1038/s42255-020-0251-4>. Epub 2020 Aug 3. Erratum in: *Nat. Metab.* 2020 Sep 10; PMID: 32747792.
- [52] J.A. Simoneau, C. Bouchard, Human variation in skeletal muscle fiber-type proportion and enzyme activities, *Am. J. Physiol.* 257 (4 Pt 1) (1989 Oct) E567–E572, <https://doi.org/10.1152/ajpendo.1989.257.4.E567>. PMID: 2529775.
- [53] R.S. Staron, F.C. Hagerman, R.S. Hikida, T.F. Murray, D.P. Hostler, M.T. Crill, K. E. Ragg, K. Toma, Fiber type composition of the vastus lateralis muscle of young men and women, *J. Histochem. Cytochem.* 48 (5) (2000 May) 623–629, <https://doi.org/10.1177/002215540004800506>. PMID: 10769046.
- [54] S.M. Roth, R.E. Ferrell, D.G. Peters, E.J. Metter, B.F. Hurley, M.A. Rogers, Influence of age, sex, and strength training on human muscle gene expression determined by microarray, *Physiol. Genom.* 10 (3) (2002 Sep 3) 181–190, <https://doi.org/10.1152/physiolgenomics.00028.2002>. PMID: 12209020; PMCID: PMC2812433.
- [55] C.H. Steffensen, C. Roepstorff, M. Madsen, B. Kiens, Myocellular triacylglycerol breakdown in females but not in males during exercise, *Am. J. Physiol. Endocrinol. Metab.* 282 (3) (2002 Mar) E634–E642, <https://doi.org/10.1152/ajpendo.00078.2001>. PMID: 11832367.

- [56] C. Roepstorff, C.H. Steffensen, M. Madsen, B. Stallknecht, I.L. Kanstrup, E. A. Richter, B. Kiens, Gender differences in substrate utilization during submaximal exercise in endurance-trained subjects, *Am. J. Physiol. Endocrinol. Metab.* 282 (2) (2002 Feb) E435–E447, <https://doi.org/10.1152/ajpendo.00266.2001>. PMID: 11788377.
- [57] S. Welle, R. Tawil, C.A. Thornton, Sex-related differences in gene expression in human skeletal muscle, *PloS One* 3 (1) (2008 Jan 2) e1385, <https://doi.org/10.1371/journal.pone.0001385>. PMID: 18167544; PMCID: PMC2148100.
- [58] S. Schiaffino, C. Reggiani, Fiber types in mammalian skeletal muscles, *Physiol. Rev.* 91 (4) (2011 Oct) 1447–1531, <https://doi.org/10.1152/physrev.00031.2010>. PMID: 22013216.
- [59] B. Kiens, Skeletal muscle lipid metabolism in exercise and insulin resistance, *Physiol. Rev.* 86 (1) (2006 Jan) 205–243, <https://doi.org/10.1152/physrev.00023.2004>. PMID: 16371598.
- [60] C.M. Nascimento, M. Ingles, A. Salvador-Pascual, M.R. Cominetti, M.C. Gomez-Cabrera, J. Viña, Sarcopenia, frailty and their prevention by exercise, *Free Radic. Biol. Med.* 132 (2019 Feb 20) 42–49, <https://doi.org/10.1016/j.freeradbiomed.2018.08.035>. Epub 2018 Aug 31. PMID: 30176345.